FindTrial
Sign In

A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A

A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A - CMT-AA

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001535
Enrollment
60
Registered
2009-01-01
Start date
2005-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Charcot-Marie-Tooth disease 1A

Interventions

Ascorbic acid (AA) treatment group (12 weeks oral AA (20mg/kg/day) no AA treatment group

Sponsors

New treatment strategies for intractable neuropathies based on its pathomechanism. The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) CMT1A patients with PMP duplications (triple gene doses) 2) Patients with normal function of main organs (heart, lung, liver and kidney) 3) Patients with no severe complications

Exclusion criteria

Exclusion criteria: 1) Patients with dementia 2) Patients with severe complications 3) Patients who are not appropriate for the trial by the decision of the physician in charge

Design outcomes

Primary

MeasureTime frame
An improvement in CMT neuropathy score at baseline, 4, 8 and 12 weeks thereafter.—

Secondary

MeasureTime frame
An improvement in muscle strength and ulnar nerve conduction study at baseline, 4, 8 and 12 weeks thereafter.—

Countries

Japan

Contacts

Public ContactMasanori Nakagawa

Kyoto Prefectural University of Medicine, Graduate School of Medical Science Department of Neurology

mnakagaw@koto.kpu-m.ac.jp075-251-5793

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026